Cargando…

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis

The aim of the present meta-analysis was to systematically assess the efficacy of the various treatments available for moderate to severe psoriasis. PubMed and Embase databases were systematically searched to select relevant studies up to February 2015. Odds ratios (ORs) and their 95% confidence int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geng, Wenjun, Zhao, Jianhua, Fu, Jixing, Zhang, Huamin, Qiao, Shaohua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257037/ https://www.ncbi.nlm.nih.gov/pubmed/30546410 http://dx.doi.org/10.3892/etm.2018.6859

Ejemplares similares

MicroRNA-451a prevents cutaneous squamous cell carcinoma progression via the 3-phosphoinositide-dependent protein kinase-1-mediated PI3K/AKT signaling pathway
por: Fu, Jixing, et al.
Publicado: (2021)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
por: Leonardi, Craig L., et al.
Publicado: (2022)

Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
por: Armstrong, April W., et al.
Publicado: (2021)

Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle
por: Chi, Ching-Chi, et al.
Publicado: (2014)

Biological therapies in moderate and severe psoriasis: perspectives and certainties
por: Constantin, MM, et al.
Publicado: (2014)

Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis
por: Golhen, Klervi, et al.
Publicado: (2022)

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
por: Jiang, Yuxiong, et al.
Publicado: (2023)

Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis
por: Messori, Andrea, et al.
Publicado: (2015)

Therapy of moderate and severe psoriasis
por: Claes, Christa, et al.
Publicado: (2006)

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
por: Armstrong, April, et al.
Publicado: (2022)

THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS: A BIOLOGIC REVOLUTION
por: Skillen, LA, et al.
Publicado: (2018)

Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2021)

Study of the Visceral Adipose Tissue in a Cohort of Patients with Moderate-Severe Psoriasis Treated with Biological Therapy
por: Ricardo, Ruiz-Villaverde, et al.
Publicado: (2022)

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis
por: Membrive Jiménez, Cristina, et al.
Publicado: (2021)

Infections in Patients Receiving Subcutaneous Biological Treatments for Moderate to Severe Psoriasis
por: Messori, Andrea, et al.
Publicado: (2015)

Moderate to severe psoriasis treatment challenges through the era of biological drugs
por: Vide, Júlia, et al.
Publicado: (2017)

Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
por: Barker, Jonathan, et al.
Publicado: (2021)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Meta-Analysis of the Efficacy and Safety of Interleukin-23-Targeted Drugs in the Treatment of Moderate-to-Severe Psoriasis
por: Zhu, Teng, et al.
Publicado: (2022)

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan
por: Chen, Yu-Chen, et al.
Publicado: (2020)

Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017)

Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response
por: Sawyer, L.M., et al.
Publicado: (2018)

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis
por: Membrive-Jiménez, Cristina, et al.
Publicado: (2023)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
por: Salgado-Boquete, Laura, et al.
Publicado: (2021)

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
por: Warren, Richard B., et al.
Publicado: (2019)

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
por: Wang, Yuqian, et al.
Publicado: (2023)

Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses
por: Baker, Erica L., et al.
Publicado: (2012)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO study
por: Richard, M.‐A., et al.
Publicado: (2020)

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
por: Gisondi, Paolo, et al.
Publicado: (2021)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Vickers, Adrian D., et al.
Publicado: (2016)

Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
por: Armstrong, April W., et al.
Publicado: (2021)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vu7h49be1fkfkiarkhcq69je7v